PPARGC1A and Insulin resistance: Collectively, increased methylation in the promoter region of PPARGC1A in individuals with T2D – or at increased risk of developing T2D – represent the hitherto most studied, and with some exceptions consistent, molecular epigenetic change potentially involved in the pathogenesis of insulin resistance and T2D.